Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)

Hong Kong · Delayed Price · Currency is HKD

309.60

-8.80 (-2.76%)

Jun 18, 2026, 4:08 PM HKT

Market Cap	27.52B
Revenue (ttm)	182.97M +133.7%
Net Income	-74.71M
EPS	-0.93
Shares Out	88.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,070
Open	316.00
Previous Close	318.40
Day's Range	302.60 - 316.00
52-Week Range	178.00 - 428.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 25, 2026

About HKG:2526

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2016

Employees 166

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2526

Full Company Profile

Financial Performance

In 2025, HKG:2526's revenue was 164.42 million, an increase of 133.72% compared to the previous year's 70.35 million. Losses were -67.14 million, 54.8% more than in 2024.

Financial numbers in CNY Financial Statements